Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways
This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.
Mechanisms of action and resistance of trastuzumab in breast cancer
Mechanisms of resistance to molecular therapies targeting the HGF/MET axis
RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge
Mechanisms of resistance to PI3K and AKT inhibitors
Sensitivity and resistance to BH3 mimetics in cancer therapy
Resistance mechanisms to cyclin-dependent kinase inhibitors
Resistance to inhibitors of angiogenesis.
Resistance of colorectal tumors to anti-EGFR antibodies
Resistance of lung cancer to kinase inhibitors specific to EGFR or ALKMechanisms of action and resistance of trastuzumab in breast cancer
Mechanisms of resistance to molecular therapies targeting the HGF/MET axis
RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge
Mechanisms of resistance to PI3K and AKT inhibitors
Sensitivity and resistance to BH3 mimetics in cancer therapy
Resistance mechanisms to cyclin-dependent kinase inhibitors
Resistance to inhibitors of angiogenesis.
| ISBN | 978-3-030-09817-9 |
|---|---|
| Media type | Book |
| Copyright year | 2019 |
| Publisher | Springer, Berlin |
| Length | XX, 242 pages |
| Illustrations | XX, 242 p. 22 illus. in color. |
| Language | English |
